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Manifestations of and risk factors for graft-versus-host disease (GVHD) after double-unit cord blood trans-
plantation (DCBT) are not ﬁrmly established. We evaluated 115 DCBT recipients (median age, 37 years) who
underwent transplantation for hematologic malignancies with myeloablative or nonmyeloablative condi-
tioning and calcineurin inhibitor/mycophenolate mofetil immunosuppression. Incidence of day 180 grades II
to IV and III to IV acute GVHD (aGVHD) were 53% (95% conﬁdence interval, 44 to 62) and 23% (95% conﬁdence
interval, 15 to 31), respectively, with a median onset of 40 days (range, 14 to 169). Eighty percent of patients
with grades II to IV aGVHD had gut involvement, and 79% and 85% had day 28 treatment responses to
systemic corticosteroids or budesonide, respectively. Of 89 engrafted patients cancer-free at day 100, 54%
subsequently had active GVHD, with 79% of those affected having persistent or recurrent aGVHD or overlap
syndrome. Late GVHD in the form of classic chronic GVHD was uncommon. Notably, grades III to IV aGVHD
incidence was lower if the engrafting unit human leukocyte antigen (HLA)-A, -B, -DRB1 allele match was >4/6
to the recipient (hazard ratio, 0.385; P ¼ .031), whereas engrafting unit infused nucleated cell dose and unit-
to-unit HLA match were not signiﬁcant. GVHD after DCBT was common in our study, predominantly affected
the gut, and had a high therapy response, and late GVHD frequently had acute features. Our ﬁndings support
the consideration of HLA- A,-B,-DRB1 allele donorerecipient (but not uniteunit) HLA match in unit selection,
a practice change in the ﬁeld. Moreover, new prophylaxis strategies that target the gastrointestinal tract are
needed.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
In recent years, the use of cord blood (CB) as an alterna-
tive hematopoietic stem cell (HSC) source has increased
substantially, especially using double-unit grafts for children
with larger body mass and adults. However, although the
incidence of graft-versus-host disease (GVHD) is low given
the marked degree of human leukocyte antigen (HLA)
mismatch of CB grafts [1,2], GVHD remains a burden after CB
transplantation (CBT). This is especially true if patients
undergo transplantation without antithymocyte globulin
(ATG) [3,4]. Furthermore, although progression-free survival
(PFS) after double-unit CBT (DCBT) is comparablewith that of
adult donor transplantation [4-6], DCBT may be associated
with an increased incidence of acute GVHD (aGVHD) when
compared to single-unit CBT [3].
Although MacMillan et al. suggested that only grade II
aGVHD is increased after DCBT [3], GVHD has emerged as
a major cause of morbidity and mortality after DCBT [4], and
data concerning its manifestations, treatment response, andedgments on page 910.
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13.02.008risk factors are limited. Moreover, the incidence and clinical
characteristics of GVHD after day 100 in DCBT recipients have
not been well described. We therefore investigated the
incidence, nature, and treatment response of aGVHD; risk
factors associated with severe aGVHD; and the manifesta-
tions of chronic GVHD (cGVHD) in 115 pediatric and adult
DCBT recipients with hematologic malignancies who
underwent transplantation with a calcineurin inhibitor/
mycophenolate mofetil (MMF) and no ATG.
METHODS
Patient and Graft Characteristics
This analysis was performed in patients who underwent transplantation
at Memorial Sloan-Kettering Cancer Center (MSKCC) between October 1,
2005 and February 28, 2011. All CBT recipients during this time period
received double-unit grafts. Patients eligible for this analysis included all
consecutive adult and pediatric DCBT recipients of ﬁrst allograft who
underwent transplantation for the treatment of hematologic malignancies
excluding acute leukemia patients who underwent transplantation with
>20% bone marrow blasts. All patients provided written informed consent
for transplantation according to the principles of the Declaration of Helsinki,
and transplantation outcome analysis was approved by the MSKCC Insti-
tutional Review and Privacy Board.
CB units were selected on the basis of 4-6/6 HLA-A, -B antigen, -DRB1
allele match to the recipient; a cryopreserved total nucleated cell (TNC) dose
of at least 1.5  107/kg/unit; and the bank of origin as previously described
[7]. Uniteunit HLA match was not considered in CB unit selection. High-
resolution HLA-A,-B,-C,-DRB1 and DQ allele typing of CB units wasTransplantation.
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thawed using albumin-dextran dilution [8] (n ¼ 205) or thawed with wash
(n ¼ 25).
Conditioning Regimens and GVHD Prophylaxis and Treatment
All patients were hospitalized in high-efﬁciency particulate, air-ﬁltered
rooms and received similar supportive care. Pretransplant conditioning
varied according to patient age, diagnosis, remission status, extent of prior
therapy, and comorbidities and consisted of myeloablative (high dose and
reduced intensity), and nonmyeloablative regimens (Table 1). Granulocyte
colony-stimulating factor (5 mg/kg/day) was given to all patients after
transplantation until neutrophil recovery.
All patients received a calcineurin inhibitor and MMF for GVHD
prophylaxis starting day -3, and none received ATG [4,9]. One hundred
four patients received cyclosporine A, targeting a trough level of 200 ng/mL
to 400 ng/mL, and 11 patients received tacrolimus, targeting a trough level
of 5 ng/mL to 15 ng/mL. In the ﬁrst 83 patients MMF was dosed at 1 g (or at
15mg/kg if patient weighed<50 kg) every 12 hours; the total daily dosewas
increased (1 g per dose if patient weighed >50 kg, 15 mg/kg per dose if
patient weighed <50 kg and was age >12 years, and 20 mg/kg/dose to
a maximum of 1 g if patient was age <12 years, all every 8 hours) in the
subsequent 32 patients to augment GVHD prophylaxis [10].
MMF was initiated intravenously in all patients, and this was main-
tained during hospitalization and switched to oral dosing before discharge.
In the absence of GVHD, MMF was tapered after day 45, and the calcineurin
inhibitor was tapered after day 100. Patients with grades II to IV aGVHD
were initially treated with either single-agent budesonide (9 mg daily) or
systemic corticosteroids (1 mg/kg to 2mg/kg oral prednisone or intravenous
methylprednisolone) at the treating physician’s discretion according to the
clinical GVHD severity at the time of diagnosis.
Study Deﬁnitions
Disease risk, time to neutrophil and platelet recovery, and sustained
donor engraftment were deﬁned as previously described [4,11]. Patient
ancestry was classiﬁed as European when there was no known non-Table 1
Patient Demographics (n ¼ 115)
Characteristic Value
Median age, yr (range) 37 (0.9-69)
Male/female, n (%) 61 (53)/54 (47)
Median weight, kg (range) 66 (7-111)
Recipient CMV seropositive, n (%) 64 (56)
Prior autologous transplantation, n (%) 16 (14)
Ancestry, n (%)
European 52 (45)
Non-European 63 (55)
Diagnosis, n (%)
Acute leukemia (including ABL) 67 (58)
MDS/CML/other myeloproliferative disease 6 (5)
NHL/HD/CLL 42 (37)
Disease risk, n (%)*
Standard 21 (18)
High 94 (82)
High-dose myeloablative conditioning, n (%)
Cy 120/Flu 75/TBI 1320-1375 cGy 43 (37)
Clo 100-150/Mel 140/Thio 10 11 (10)
Thio 10/Flu 125/TBI 1375 cGy 2 (2)
Reduced-intensity conditioning, n (%)
Flu 150/Cy 50/Thio 10/TBI 400 cGy
Mel
25 (22)
140/Flu 150 7 (6)
Nonmyeloablative conditioning, n (%)
Flu 150/Cy 50/TBI 200 cGy 27 (23)
CMV indicates cytomegalovirus; ABL, acute biphenotypic leukemia; MDS,
myelodysplastic syndrome; CML, chronic myeloid leukemia; NHL, non-
Hodgkin lymphoma; HD, Hodgkin’s disease; CLL, chronic lymphocytic
leukemia; Cy, cyclophosphamide; Flu, ﬂudarabine; TBI, total body irradia-
tion; Clo, clofarabine; Mel, melphalan; Thio, thiotepa.
* Standard-risk disease for AML and ALL was deﬁned as ﬁrst complete
response without high-risk cytogenetics or high-risk molecular abnormal-
ities, de novo MDS with an International Prognostic Scoring System score
<2, CML in ﬁrst chronic phase, and chemotherapy-sensitive lymphoma in
less than second relapse for aggressive histologies of less than third relapse
for indolent disease without prior autologous transplantation. All remaining
patients were considered high risk.European ancestry. Non-Europeans were Asian, African, white Hispanic,
and Middle Eastern patients as well as those with mixed non-European and
European origins [12]. Donor chimerismwas determined serially in the bone
marrow and blood using semiquantitative analysis of polymerase chain
reactioneampliﬁed informative polymorphisms [11,13].
aGVHD and cGVHD were diagnosed clinically with histologic conﬁr-
mation as required and clinically appropriate. Grade of aGVHDwas based on
the International BoneMarrow Transplant Registry classiﬁcation [14], except
grades A to D were labeled grades I to IV, and was applied to GVHD with
purely acute features even if it occurred after day 100. Gradingwas reviewed
by a transplant clinician panel to reach consensus of maximum aGVHD
grade. cGVHD was deﬁned according to published National Institutes of
Health (NIH) consensus criteria [15], and these criteria were used to assess
GVHD severity for classic and overlap cGVHD.Malignant relapsewas deﬁned
as recurrence or progression of disease over pretransplantation baseline and
transplant-related mortality as death from any cause in continued remis-
sion. PFS was deﬁned according to standard criteria. The algorithm of
Copelan et al. was used to assign the primary cause of death [16].
Responses to aGVHD therapy were determined using published deﬁni-
tions [3]. Day 28 was chosen as the optimal time point to assess GVHD
response [17,18]. Complete response was the complete resolution of aGVHD
symptoms in all organs without secondary GVHD therapy. Partial response
was the improvement in GVHD stage in all initially affected organs without
complete resolution and without worsening in other GVHD target organs or
requiring secondary GVHD therapy. Progressionwas deﬁned asworsening of
GVHD in at least 1 organ with or without amelioration in any organ. No
response was deﬁned as patients with the same grade of GVHD not meeting
criteria for partial response or progression.
Statistical Analysis
Data on patient characteristics and transplant-related outcomes were
obtained from the prospectively maintained MSKCC transplant database
veriﬁed by primary source documentation. Signiﬁcant differences in cate-
gorical variables were determined by chi-square or the Fisher exact test
(2-tailed). Signiﬁcant differences between means were determined by
Student’s t-test and between distributions by the Mann-Whitney U test.
Incidence of neutrophil engraftment, GVHD, and relapse were estimated
using the cumulative incidence function. Death was the competing event for
engraftment and relapse. Relapse and death were the competing events for
GVHD. We included relapse as a competing event for GVHD calculations
because treatment of relapse could alter GVHD incidence and severity. PFS
was estimated using Kaplan-Meier methodology. Univariate and multivar-
iate Cox regression analyses were used to ascertain associations between
patient or graft characteristics with severe (grades III to IV) aGVHD. Analyses
were performed using SPSS version 19 (IBM Corporation, Armonk, NY).
RESULTS
Characteristics of Patients and Grafts
Patient demographics are summarized in Table 1. One
hundred ﬁfteen patients, predominantly adults (median age,
37 years; 23 children and 92 adults), underwent trans-
plantation. More than one half were of non-European
ancestry. Most had high-risk acute leukemia and received
high-dose or reduced-intensity conditioning. TNC, CD34þ
and CD3þ cell doses, and HLA uniterecipient and uniteunit
match are shown in Table 2. Unit selection was based on
match at HLA-A,-B antigens and -DRB1 alleles with up to 2
mismatches allowed. However, high-resolution typing of
HLA-A,-B along with -DRB1 alleles demonstrated 87 units
(38%) were <4/6 HLA allele matched to the recipient. The
median match grade of units at 6 HLA alleles (high-resolu-
tion match grade) was 4/6 (range, 1 to 6/6) and for 10 alleles
(including HLA-C and -DQ) was 6/10 (range, 2 to 9/10).
Because uniteunit match was not a selection criterion, there
was a broad range of uniteunit match at all levels of reso-
lution of HLA typing (Table 2).
Engraftment and Donor Chimerism
Six patients had graft failure (5 primary,1 secondary), and
1 patient was not assessable due to early death. The cumu-
lative incidence of sustained donor-derived neutrophil
engraftment was 94% (95% conﬁdence interval [CI], 90 to 98)
Figure 1. Cumulative incidence of grades II to IV and III to IV aGVHD at day
180. The incidence is reported at day 180 to include 2 patients with late-onset
aGVHD between days 100 and 180 after DCBT and 3 patients who developed
aGVHD before day 100 but peaked at grades III to IV disease after day 100.
These latter 3 patients, although grade II at onset, are included in the III-IV
curve.
Table 3
aGVHD Therapy Responses in Patients Treated with Either Systemic Corti-
costeroids or Budesonide
Table 2
Graft Characteristics (n ¼ 115 double-unit grafts, 230 units)
Characteristic Value
Infused cell dose, median (range)
TNC  107/kg, larger unit/smaller unit 2.7 (1.4-12.8)/2.0 (0.9-7.1)
CD34þ  105/kg, larger unit/smaller
unit
1.2 (0.3-7.0)/0.7 (0.1-2.1)
CD3þ  106/kg, larger unit/smaller
unit
4.4 (1.3-15.0)/3.1 (0.3-10.6)
Uniterecipient HLA match, n (%)
A and -B antigen, -DRB1 allele
6/6 11 (5)
5/6 121 (52.5)
4/6 98 (42.5)
A, -B,-DRB1 allele
6/6 7 (3)
5/6 63 (27)
4/6 73 (32)
3/6 62 (27)
2/6 23 (10)
1/6 2 (1)
Uniterecipient HLA match, median
(range)
A, -B, -DRB1 allele 4/6 (1-6/6)
A, -B, -C, -DRB1, -DQ allele 6/10 (2-9/10)
Uniteunit HLA match
A and -B antigen, -DRB1 allele 4/6 (2-6/6)
A, -B, -DRB1 allele 4/6 (0-6/6)
A, -B, -C, -DRB1, -DQ allele 5/10 (0-10/10)
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91) by day 180. The median times to neutrophil and platelet
recovery were 24 days (range, 12 to 43) and 50 days (range,
29 to 162), respectively, after myeloablative conditioning,
and 10 days (range, 7 to 36) and 34 days (range, 9 to 59),
respectively, after nonmyeloablative conditioning.
One unit dominated in all engrafting patients. Eighty-nine
of 108 patients (82%) with sustained donor engraftment had
complete dominance of a single unit documented as early as
21 to 28 days after transplantation (median donor engraft-
ment, 100%). The percentage of patients with hematopoiesis
entirely derived from a single unit further increased to 92 of
101 assessable patients (91%) at day 60 and 84 of 89
assessable patients (94%) at day 100 (median 100% donor
with the engrafting unit at both time points). The HLA match
of the engrafting unit with the recipient was a median of 4/6
HLA-A,-B,-DRB1 alleles (range, 1 to 6/6) and 6/10 HLA-A,-B,
-C,-DRB1,-DQ alleles (range, 2 to 9/10).Systemic
Corticosteroids
(n ¼ 29)
Budesonide
Alone
(n ¼ 27)
Median time to GVHD onset, days
(range)
34 (14-89) 54 (31-161)
Organ involvement, n (%)
Skin alone 5 (17) 0
GI 23 (79) 27 (100)
Skin and GI 12 (52) 12 (44)
GI alone 3 (13) 14 (52)
GI and liver 4 (17) 1 (4)
GI, liver, skin 4 (17) 0
Liver alone 1 (3) 0
aGVHD grade at treatment onset, n (%)
II 8 (28) 27 (100)
III 16 (55) 0
IV 5 (17) 0
Treatment response at day 28
of therapy, n (%)
CR 11 (38) 10 (37)
PR 12 (41) 13 (48)
<PR 6 (21) 4 (15)
CR indicates complete response; PR, partial response.aGVHD Incidence and Manifestations
Sixty-one patients had grades II to IV aGVHD within the
ﬁrst 6 months after DCBT (2 with late onset after day 100).
The diagnosis was supported by biopsy in 55 of 61 patients
(90%) (skin, n ¼ 29; gastrointestinal [GI] tract, n ¼ 44; and
liver, n ¼ 5). Twenty-six of these patients had grades III to IV
disease (with 3 peaking at grades III to IV after day 100). The
day 180 cumulative incidence of grades II to IV and III to IV
aGVHDwere 53% (95% CI, 44 to 62) and 23% (95% CI,15 to 31),
respectively (Figure 1). Among patients with grades II to IV
aGVHD, themedian onset of aGVHDwas 40 days (range,14 to
169); onset was earlier for those with grades III to IV disease
(median, 35 days) than those with grade II aGVHD (median,
42 days; P ¼ .012).
Of patients with grades II to IV aGVHD, the GI tract was
themost commonly affected organ (n¼ 49, 80% of thosewith
grades II to IV disease). Fourteen patients had upper GI tract
involvement, 9 had lower, and 26 had both. Skinwas affectedless often (n ¼ 39, 64% of those with grades II to IV disease).
Only 17 patients had stage III skin disease, and 2 had stage IV.
The liver was involved in 18% of grades II to IV cases. The
combination of skin and GI tract disease was the most
common manifestation (n ¼ 25, 41% of those affected), fol-
lowed by GI tract alone (25%), and skin alone (16%). Four
patients had involvement of all 3 organs, 5 had gut and liver
involvement, and 2 had only liver involvement.aGVHD Treatment and Responses
Among patients with grades II to IV aGVHD, 29 (48%)
were treated with systemic corticosteroids, 27 (44%) with
budesonide alone, 4 (7%) with topical corticosteroids, and 1
recovered without additional immunosuppression. Most
patients who received systemic corticosteroids had grades III
to IV disease, and most (79%) responded by day 28 of therapy
(Table 3). Six patients (4 adults, 2 children) did not respond,
Table 4
Summary of GVHD Syndromes after Day 100 (n ¼ 48 patients of 89
engrafted and disease-free at day 100)
GVHD Syndrome n (%)* Severity
aGVHD 31(64.5)
Persistent or recurrent 29 21 grade II
Late onset II-IV aGVHD (days 100-180) 2 10 grades III-IV
Classic chronic 10 (21) 9 mild
5 moderate
3 severe
Interrupted 4
De novo 6
Overlap syndromey 7 (14.5%)
* Percentages reﬂect proportion of the 48 patients affected with GVHD
after day 100.
y Three patients with persistent aGVHD subsequently evolved to overlap
syndrome (1 mild, 2 severe). Thus, 10 patients developed overlap syndrome
during the study period.
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GI aGVHD.
Budesonide was used as the sole treatment exclusively in
adults for overall grade II aGVHD predominantly affecting the
upper and/or lower GI tract. Compared with those given
systemic corticosteroids, these patients had a later GVHD
onset (Table 3). Twenty-three budesonide-treated patients
(85%) responded by day 28 of therapy. Four patients without
an initial response also required salvage with systemic
corticosteroids, and 3 responded.
GVHD after Day 100: Late aGVHD and cGVHD
Because day 100 has traditionally distinguished acute
from chronic GVHD, the manifestations of late GVHD occur-
ring after day 100 were examined (Table 4). Of the 89
patients who engrafted and were in remission at day 100, 41
had no GVHD after day 100. Seventeen of these 41 patients
(42%) had had prior aGVHD (12 grade II and 5 grade III) that
had resolved. The remaining 48 patients had active GVHD on
or beyond day 100. Twenty-nine of these patients had
persistent (n ¼ 14) or recurrent (n ¼ 15) aGVHD (3 subse-
quently evolved into overlap syndrome), and 2 had late-
onset aGVHD on days 161 and 169. An additional 17
patients developed cGVHD after day 100. Ten had classic
cGVHD (4 interrupted onset, 6 de novo), and 7 had overlap
syndrome (6 with prior aGVHD and 1 de novo).
Thus, of the 48 patients with active GVHD after day 100,
38 (79%) had purely acute features or overlap syndrome.Figure 2. Cumulative incidence of GVHD in engrafted and disease-free at 100 days aft
(B) Exclusively cGVHD (classic and overlap) after day 100 in this patient population.Overall, among patients who engrafted and were cancer-free
as of day 100, the 2-year cumulative incidence of GVHD of
any kind was 54% (95% CI, 44 to 65) (Figure 2A). However,
if only chronic GVHD by NIH criteria was considered, the
2-year incidence was 23% (95% CI, 14 to 32) (Figure 2B).
Disease manifestations were examined in 20 patients
who developed NIH-deﬁned [15] cGVHD (including 3
patients who evolved from aGVHD to overlap syndrome).
The 10 patients with classic cGVHD had a median onset
of 233 days (range, 141 to 505) with skin pigment changes
(n ¼ 5), dry eyes (n ¼ 3), joint pain (n ¼ 1), anorexia (n ¼ 2),
liver function test abnormalities (n ¼ 4), and nephrotic
syndrome (n ¼ 1). The 10 patients with overlap syndrome
(median onset, 156 days; range, 100 to 418) had aGVHD
symptoms of erythematous skin rash (n ¼ 5), nausea/
vomiting, and/or diarrhea (n¼ 10) combinedwith drymouth
or taste alteration (n¼ 3), mouth ulcers (n¼ 1), dry eyes (n¼
3), joint stiffness (n¼ 1), vaginal dryness (n¼ 1), and/or liver
function test abnormalities (n ¼ 1). No patient had severe
ocular or sclerotic skin involvement, contractures, or symp-
tomatic pulmonary involvement. Most had disease of mild
(n ¼ 10, 50%) or moderate (n ¼ 5, 25%) severity, and the GI
tract and skin were the organs most commonly affected. Five
patients (25%) developed severe disease. All but 4 patients
who developed cGVHD during the study period had done so
by 1 year after transplantation.Cessation of Immunosuppression
Sixty-eight patients had sustained donor-derived
engraftment and were in remission at 1 year after DCBT.
Of those, 24 (35%) had stopped all immunosuppression
(14 patients without GVHD and 10 with prior GVHD),
whereas 44 patients (65%) remained on immunosuppression
(18 for active GVHD and 26 on a taper) at 1 year after DCBT.
Of the 18 with active GVHD at 1 year, 10 had aGVHD, 5 had
overlap syndrome, and 3 had classic cGVHD.Mortality and GVHD Deaths
To date, 44 patients have died: 14 from relapse, 29 from
transplant-related complications, and 1 patient who under-
went transplantation for treatment-related acute myeloid
leukemia from relapsed osteosarcoma. With a median
follow-up of 33 months (range, 8 to 73), the 2-year overaller transplantation. (A) Cumulative incidence of any active GVHD after day 100.
Figure 3. Cumulative incidence of day 180 grades III to IV aGVHD by engrafting uniterecipient match at HLA-A,-B,-DRB1 (A) and HLA-A,-B,-C,-DRB1,-DQ (B) alleles.
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51 to 70), respectively.
GVHD was the primary cause of death in 9 patients and
was the second most common cause of transplant-related
mortality after organ toxicity. These deaths occurred at
a median of 184 days (range, 70 to 445) after DCBT. The
9 GVHD deaths were in adults and due to acute disease
(1 grade II, 7 grades III to IV) or grade III aGVHD evolving to
severe overlap syndrome (n ¼ 1). Five of these patients had
initially received systemic corticosteroids, and 4 had failed
initial treatment with budesonide. The most common
secondary cause of death was infection (n ¼ 7). Two had
pneumonia (presumed bacterial), 3 had proven bacterial
infections (1 fulminant Clostridium difﬁcile colitis, 1 Klebsiella
septicemia, and 1 Klebsiella pneumonia), and 2 had dissem-
inated adenovirus. The remaining patients died of GI tract
perforation (n ¼ 1) and idiopathic diffuse alveolar hemor-
rhage (n ¼ 1).Table 5
Multivariate Analysis of Variables Potentially Associated with Day 180
Grades III to IV aGVHD Incidence (n ¼ 115)
Patient and Graft Characteristics Hazard Ratio* P
Age, yr
0-15 (n ¼ 23) Reference
16 (n ¼ 92) 0.920 (0.358-2.36) .862
CMV serostatus
Seronegative (n ¼ 51) Reference
Seropositive (n ¼ 64) 0.570 (0.255-1.275) .171
Engrafting unit TNC  107/kg
<3.0 (n ¼ 94) Reference
3.0 (n ¼ 21) 2.040 (0.802-5.217) .134
Engrafting uniterecipient 6 allele
HLA match
1-3/6 (n ¼ 36) Reference
4-6/6 (n ¼ 79) 0.385 (0.162-0.915) .031
Uniteunit 6 allele HLA match
0-4/6 (n ¼ 88) Reference
5-6/6 (n ¼ 27) 2.204 (0.866-5.609) .097
* Values in parentheses are 95% conﬁdence intervals.Risk Factors for Grades III to IV aGVHD
Because the predominant GVHD syndrome was acute
disease and grades III to IV disease accounted for nearly all
GVHD mortality, we evaluated risk factors for grades III to IV
aGVHD through day 180 (to account for patients whose
aGVHD peaked in severity after day 100). Univariate analysis
of the relationship between patient characteristics and day
180 grades III to IV aGVHD revealed no association with
patient age (0 years to 15 years versus 16 years), diagnosis
(acute leukemia/myelodysplastic syndrome versus
lymphoma/chronic lymphocytic leukemia), conditioning
intensity (myeloablative versus nonmyeloablative), patient
ancestry (European versus non-European), recipient cyto-
megalovirus serostatus (seronegative versus seropositive
recipient), or MMF dosing interval (every 12 hours versus
every 8 hours).
In univariate analysis, there was no association with the
infused TNC doses per kilogram or the CD3þ cell doses per
kilogram of either the engrafting unit or the total dose (unit
1 þ unit 2) in the graft. CD34þ cell doses also had no rela-
tionship with severe aGVHD risk. There was no association
between the uniteunit HLA match (at any degree of resolu-
tion) and severe aGVHD. Differences in severe aGVHD inci-
dence according to HLA match of the engrafting unit to the
recipient (Figure 3) did not reach signiﬁcance.A multivariate Cox regression analysis was performed to
take potential confounding variables into account (Table 5).
In this analysis, better 6 allele HLA match between the
engrafting unit and the recipient was associated with a lower
incidence of severe aGVHD (P ¼ .031). Patient age, recipient
cytomegalovirus serostatus, engrafting unit infused TNC, and
uniteunit HLA match were not signiﬁcant. When 10 allele
HLA match of the engrafting unit was substituted for a 6
allele match in the multivariate analysis, the severe aGVHD
hazard ratio was .325 for engrafting units that were >8/10
HLA matched to the recipient, but the comparison was no
longer signiﬁcant (P ¼ .073).DISCUSSION
The clinical features and risk factors of GVHD after
DCBT are yet to be ﬁrmly established. Our study is the ﬁrst
to examine GVHD using a pediatric and adult population
uniformly undergoing transplantation with double-unit CB
grafts, calcineurin inhibitor plus MMF prophylaxis, and no
ATG. Whether double-unit grafts increase GVHD risk over
that of singles could not be examined because we did not
perform single-unit CBT. This will be addressed, at least in
children, in the Blood and Marrow Transplant Clinical
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pediatric CBT trial. However, we conﬁrmed that over one
half of DCBT recipients are affected by clinically signiﬁcant
aGVHD. Furthermore, although our day 180 incidence of
grades II to IV and III to IV aGVHD of 53% and 24% were
similar to the 58% and 19% day 100 incidence reported by
MacMillan et al. [3], we found a greater proportion of GI
tract as opposed to the predominantly skin involvement
reported in that series. Interestingly, Alsultan et al. also
reported in an analysis of 79 pediatric CBT recipients that
the organ most commonly affected was the GI tract [19].
Differences in patient populations, aggressive efforts to
diagnose aGVHD with early endoscopic evaluation and
biopsy, and our uniform lack of ATG use could have
contributed to these ﬁndings. The striking propensity for
GI involvement in our study suggests that GVHD prophy-
laxis targeting the gut could be a promising strategy with
agents such as inhibitors of lymphocyte migration to the
GI tract [20-23], disruption of the interleukin-21 pathway
[24-26], Janus kinase 2 inhibition [27], or agents promoting
interleukin-22 expression [28].
Although our study has the limitations of a retrospec-
tive series, our aGVHD treatment responses compare
favorably with those after related and unrelated donor
HSC transplantation [17]. Enhanced response to therapy
has been described with cGVHD after CBT [29], and future
prospective comparisons of aGVHD therapy responses
after the transplantation of CB versus adult donors will be
of great interest. In addition, many patients with grade II
gut aGVHD were successfully treated with single-agent
budesonide. The poorly absorbed corticosteroids budeso-
nide and beclomethasone (reviewed by Ibrahim et al. [30])
have reported activity in GVHD therapy after adult donor
allografts [31,32]. However, we did not determine the
extent of systemic absorption. In DCBT recipients, systemic
budesonide exposure could be enhanced by cytochrome
P4503A4 inhibition by azoles (as described with inhaled
budesonide [33]), in which case budesonide may be no
different from low-dose oral prednisone. Overall, our data
suggest that budesonide may have activity in grade II GI
GVHD in CBT recipients. Although not all patients
responded and lack of prompt response should trigger
immediate initiation of systemic corticosteroids, our data
suggest prospective clinical trials of budesonide therapy in
CBT recipients with grade II disease are warranted with
the aim to potentially decrease systemic corticosteroid
exposure but with careful determination of the extent of
systemic absorption.
A further unique ﬁnding of this analysis was that 79% of
patients with active GVHD after day 100 had acute features
with persistent, recurrent, or late aGVHD, or overlap
syndrome, and the disease predominantly affected the gut.
Classic cGVHD affected only 10 patients in the study, and
cGVHD was usually of mild or moderate severity. Only 1
patient had ulceration of the oral mucosa, and no patients
had moderate or severe ocular GVHD, contractures, or
pulmonary involvement. By contrast, Arai et al. reported
that skin, lung, and eye scores determined the severity of
cGVHD in a 298 patient series of predominantly related and
unrelated donor peripheral blood HSC transplantation
recipients [34]. Thus, the pathophysiology of late GVHD in
most DCBT recipients appears to be distinct from that of
classic cGVHD after transplantation of adult peripheral
blood HSC. Overall, although classic cGVHD was
uncommon, when all patients with active GVHD (grades IIto IV aGVHD, overlap GVHD, and classic cGVHD) were
combined, this accounted for the high 54% incidence of
active GVHD in day 100 survivors in our study as compared
with other CBT series [1,2,35-37]. Such an analysis is the
only way to reﬂect the true burden of late GVHD in allograft
survivors.
The rates of grades III to IV aGVHD in this study, although
no worse than those observed after unmodiﬁed unrelated
donor peripheral blood stem cell transplantation [38],
emphasize the need for enhanced GVHD prophylaxis after
DCBT. Omission of ATG in the conditioning regimen has been
identiﬁed as an aGVHD risk factor [3], and some centers have
elected to include ATG with consequent low rates of GVHD
[6,39]. However, ATG has been associated with an increased
risk of serious infections, including lethal Epstein-Barr virus
lymphoproliferative disease [40,41], delayed immune
reconstitution [42], and increased risk of transplant-related
mortality [43]. ATG can also increase the risk of relapse
after reduced-intensity allograft [44]. Therefore, other
approaches to prevent and treat GVHD are more appealing,
especially because robust T cell recovery is observed after
DCBT in the absence of ATG [9]. During this study, we
increased the MMF dose to augment GVHD prophylaxis.
More recently, as a result of this analysis, we also delayed the
commencement of the MMF taper. Although future studies
will analyze the impact of these interventions, ultimately
improved understanding of the distinct pathophysiology of
GVHD after DCBT is needed to facilitate improved prevention
and treatment of this disease. Use of biomarkers to predict
subsequent severe pathology or treatment outcomes could
also be of use, as has been described in adult donor HSC
transplantation [45-47].
It is notable that just as the CD34þ cell dose per kilogram
of the engrafting unit determines the speed and success of
engraftment after DCBT [11], our data suggest its HLA match
to the patient at 6 alleles inﬂuences aGVHD severity. Delaney
et al. previously reported a trend toward a lower risk of
aGVHD if units of a double-unit CB graft were HLA-DR
matched to the recipient in 22 DCBT recipients who under-
went transplantation with cyclosporin A/MMF [48]. Priori-
tizing high-resolution donorerecipient matching in unit
selection could therefore provide another strategy to lower
the incidence of severe aGVHD. In multivariate analysis, we
found a greater signiﬁcancewith 6 versus 10 allele engrafting
uniterecipient HLA match. Although analysis of larger
numbers of patients is required for deﬁnitive conclusions,
this suggests that only 6 allele match may be sufﬁcient to
facilitate a reduction in severe aGVHD.
In this study, 36 patients engrafted with a unit that was
1-3/6 HLA-A,-B,-DRB1 allele matched. It is possible that
some may have had a better matched unit available of
similar cell dose if high-resolution matching of HLA-A and
-B had been used. Six allele matching would be relatively
easy to implement in smaller children with units >5.0 
107 TNC/kg above which further dose increments have not
been shown to be beneﬁcial in single-unit CBT [37], and the
same is likely to be true in DCBT. Such matching criteria
may be more challenging in patients with larger body mass,
however, and further analyses will be required to deter-
mine the dose threshold above which high-resolution HLA
match could safely be given priority. Another ﬁnding of
practical signiﬁcance was that no advantage was associated
with HLA match of the units to each other, as we have also
previously reported with engraftment [11]. Although
continued study is appropriate, no data support
D.M. Ponce et al. / Biol Blood Marrow Transplant 19 (2013) 904e911910consideration of uniteunit match in CB selection from the
standpoint of engraftment or aGVHD at this time.
Despite the incidence of grades III to IV aGVHD, we
found a relatively high survival after DCBT overall. This was
attributable to the low late mortality and protection against
relapse as previously reported by our group [4] and others
[5]. Nonetheless, even though no children have died from
GVHD, the morbidity of severe disease has been consider-
able in some pediatric and adult DCBT recipients, and GVHD
has been the second most common cause of transplant-
related mortality, affecting 9 adults in our study. This
highlights the need for improved prophylaxis and therapy.
Furthermore, although one third of patients came off
immunosuppression by 1 year after DCBT, the speed of
GVHD resolution, the time to cessation of immunosup-
pression, and patient quality of life after CBT compared with
adult donor transplantation should be explored in future
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